Table 4 Adverse events
From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
Adverse events | Grades | ||||
|---|---|---|---|---|---|
1 (n, %) | 2 (n, %) | 3 (n, %) | 4 (n, %) | Total (n, %) | |
Hand-foot syndrome | 5 (12.2%) | 9 (22.0%) | 5 (12.2%) | 0 (0%) | 19 (46.4%) |
Mucositis | 3 (7.3%) | 6 (14.6%) | 8 (19.5%) | 0 (0%) | 17 (41.5%) |
Anorexia | 12 (29.3%) | 3 (7.3%) | 1 (2.4%) | 0 (0%) | 16 (39.0%) |
Fatigue | 4 (9.8%) | 7 (17.1%) | 5 (12.2%) | 0 (0%) | 16 (39.0%) |
Proteinuria | 11 (26.8%) | 4 (9.8%) | 0 (0%) | 0 (0%) | 15 (36.6%) |
Hypertension | 5 (12.2%) | 6 (14.6%) | 3 (7.3%) | 0 (0%) | 14 (34.1%) |
Pain | 6 (14.6%) | 4 (9.8%) | 1 (2.4%) | 0 (0%) | 11 (26.8%) |
Thrombocytopenia | 6 (14.6%) | 3 (7.3%) | 2 (4.9%) | 0 (0%) | 11 (26.8%) |
Neutropenia | 2 (4.9%) | 2 (4.9%) | 1 (2.4%) | 0 (0%) | 5 (12.2%) |
Transaminase increased | 1 (2.4%) | 3 (7.3%) | 1 (2.4%) | 0 (0%) | 5 (12.2%) |
Diarrhea | 1 (2.4%) | 2 (4.9%) | 0 (0%) | 0 (0%) | 3 (7.3%) |